235
Participants
Start Date
September 30, 2011
Primary Completion Date
June 30, 2013
Study Completion Date
June 30, 2013
Doxycycline
During phase 1 (baseline - week 12): Oracea (doxycycline 40 mg USP (30 mg immediate release \& 10 mg delayed release beads)), oral, one capsule daily in the morning During phase 1 (baseline - week 12) and phase 2 (week 12 - week 52): Oracea (doxycycline 40 mg USP (30 mg immediate release \& 10 mg delayed release beads), oral, one capsule daily in the morning
Metronidazole
During Phase 1: MetroGel 1% (metronidazole 1% gel), topical, apply a thin layer once daily to the affected area
Placebo
During phase 2 (week 12 - week 52): placebo, oral, one capsule daily in the morning
Hilary Baldwin, Brooklyn
The Center for Dermatology at Linden Oaks, Rochester
The Maryland Laser, Skin, and Vein Institute, LLC, Hunt Valley
Dadeland Dermatology, Coral Gables
Dermatology Specialists Research, Louisville
Melissa L. F. Knuckles M.D., P.S.C., Richmond
Melissa L. F. Knuckles M.D., P.S.C., Corbin
Brodell Medical, Inc., Warren
Grekin Skin Institute, Warren
ATS Clinical Research, Santa Monica
Center for Dermatology and Laser Surgery, Portland
Lead Sponsor
Galderma R&D
INDUSTRY